lthough it has become affordable to sequence the entire human genome, measuring all proteins in a sample as complex as human plasma remains currently out of reach. The plasma proteome has an enormous dynamic range and variability, including splice variants, cleavage products, and posttranslational modifications. Antibody-based techniques have predominated, but other affinity-based techniques such as the SOMAscan aptamer assays from SomaLogic also promise the multiplexed measurement of proteins in a scalable manner.
Joshi et al. (Tue,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: